Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2010

Open Access 01-12-2010 | Research article

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

Authors: Sten Andersen, Harald Mischak, Petra Zürbig, Hans-Henrik Parving, Peter Rossing

Published in: BMC Nephrology | Issue 1/2010

Login to get access

Abstract

Background

Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.

Methods

High-resolution capillary-electrophoresis coupled to mass-spectrometry (CE-MS) was used to profile the low-molecular-weight proteome in urine of a subgroup of patients from a two year randomized irbesartan versus placebo therapy trial, which included hypertensive type 2 diabetic patients with microalbuminuria on ongoing antihypertensive medication (IRMA2-substudy).

Results

We demonstrate that the therapy with 300 mg Irbesartan daily over a period of two years results in significant changes of the urinary proteome. Both, a classifier developed previously that consists of urinary peptides indicative of chronic kidney disease, as well as several individual peptides changed significantly after treatment. These changes were not observed in the placebo-treated individuals. Most prominent are changes of urinary collagen fragments associated with progression of diabetic nephropathy, indicating normalization in urinary peptides.

Conclusion

CE-MS analysis of urine enabled identification of peptides as potential surrogate markers for renoprotection in microalbuminuric type 2 diabetic patients, which show persistent improvement after longterm treatment with Irbesartan. The results suggest that a major benefit of treatment by Irbesartan may be improvement of collagen turnover, reduction of fibrosis. They further suggest that urinary proteome analysis could be utilized to assess potential benefit of therapeutic intervention, providing statistically significant results even on a small population.
Appendix
Available only for authorised users
Literature
1.
Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.CrossRefPubMed
2.
Parving HH, Mauer M, Ritz E: Diabetic nephropathy. Brenner and Rector's the Kidney. Edited by: Brenner BM. 2004, Philadelphia: WB Saunders, 1777-1818.
3.
Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984, 310: 356-360. 10.1056/NEJM198402093100605.CrossRefPubMed
4.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004, 110: 921-927. 10.1161/01.CIR.0000139860.33974.28.CrossRefPubMed
5.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H: Effects of Losartan on Renal and Cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345: 861-869. 10.1056/NEJMoa011161.CrossRefPubMed
6.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001, 345: 870-878. 10.1056/NEJMoa011489.CrossRefPubMed
7.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-860. 10.1056/NEJMoa011303.CrossRefPubMed
8.
American Diabetes Association: Diabetic Nephropathy. Diabetes Care. 2002, 25: 85-89. 10.2337/diacare.25.2007.S85.CrossRef
9.
Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, et al: Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond). 2004, 107: 485-495. 10.1042/CS20040103.CrossRef
10.
Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, et al: Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications. 2005, 19: 223-232. 10.1016/j.jdiacomp.2004.10.002.CrossRefPubMed
11.
Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, et al: Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int. 2005, 68: 193-205. 10.1111/j.1523-1755.2005.00394.x.CrossRefPubMed
12.
Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami M, et al: Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol. 2007, 18: 1057-1071. 10.1681/ASN.2006090956.CrossRefPubMed
13.
Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, et al: Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis. 2007, 28: 4469-4483. 10.1002/elps.200700237.CrossRefPubMed
14.
Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, Serra AL: Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009, 76: 89-96. 10.1038/ki.2009.93.CrossRefPubMed
15.
Drube J, Schiffer E, Mischak H, Kemper MJ, Neuhaus T, Pape L, et al: Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant. 2009, 24: 2161-2169. 10.1093/ndt/gfp063.CrossRefPubMed
16.
Candiano G, Musante L, Bruschi M, Petretto A, Santucci L, Del BP, et al: Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol. 2006, 17: 3139-3148. 10.1681/ASN.2006050486.CrossRefPubMed
17.
Nguyen MT, Ross GF, Dent CL, Devarajan P: Early prediction of acute renal injury using urinary proteomics. Am J Nephrol. 2005, 25: 318-326. 10.1159/000086476.CrossRefPubMed
18.
Dihazi H, Muller GA, Lindner S, Meyer M, Asif AR, Oellerich M, et al: Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem. 2007, 53: 1636-1645. 10.1373/clinchem.2007.088260.CrossRefPubMed
19.
Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al: Urinary proteomics in diabetes and CKD. J Am Soc Nephrol. 2008, 19: 1283-1290. 10.1681/ASN.2007091025.CrossRefPubMedPubMedCentral
20.
Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, et al: Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010,
21.
Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D, et al: Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in ANCA associated Vasculitis. Mol Cell Proteomics. 2009, 8: 2296-2307. 10.1074/mcp.M800529-MCP200.CrossRefPubMedPubMedCentral
22.
Alkhalaf A, Zuerbig P, Bakker SJL, Bilo HJ, Cerna M, Fischer C, et al: Multicentric validation of pproteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE. 2010,
23.
Mischak H, Rossing P: Proteomic Biomarkers in diabetic nephropathy - reality or future promise?. Nephrol Dial Transplant. 2010,
24.
Ameur RB, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, et al: Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant. 2010,
25.
Vidal BC, Bonventre JV, Hong HS: Towards the application of proteomics in renal disease diagnosis. Clin Sci (Lond). 2005, 109: 421-430. 10.1042/CS20050085.CrossRef
26.
Decramer S, Gonzalez de PA, Breuil B, Mischak H, Monsarrat B, Bascands JL, et al: Urine in clinical proteomics. Mol Cell Proteomics. 2008, 7: 1850-1862. 10.1074/mcp.R800001-MCP200.CrossRefPubMed
27.
Molina F, Dehmer M, Perco P, Graber A, Girolami M, Spasovski G, et al: Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant. 2010, 25 (4): 1015-8. 10.1093/ndt/gfq033.CrossRefPubMed
28.
Dominiczak AF, Herget-Rosenthal S, Delles C, Fliser D, Fournier I, Graber A, et al: Systems biology to battle vascular disease. Nephrol Dial Transplant. 2010, 25 (4): 1019-22. 10.1093/ndt/gfq025.CrossRefPubMed
29.
Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H, et al: Exosomal Fetuin-A identified by proteomics: A novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006, 70 (10): 1847-57. 10.1038/sj.ki.5001874.CrossRefPubMedPubMedCentral
30.
Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, et al: Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004, 4: 1159-1174. 10.1002/pmic.200300661.CrossRefPubMed
31.
Thongboonkerd V, McLeish KR, Arthur JM, Klein JB: Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002, 62: 1461-1469. 10.1111/j.1523-1755.2002.kid565.x.CrossRefPubMed
32.
Pisitkun T, Shen RF, Knepper MA: Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004, 101: 13368-13373. 10.1073/pnas.0403453101.CrossRefPubMedPubMedCentral
33.
Marshall T, Williams K: Two-dimensional electrophoresis of human urinary proteins following concentration by dye precipitation. Electrophoresis. 1996, 17: 1265-1272. 10.1002/elps.1150170716.CrossRefPubMed
34.
Shihabi ZK, Konen JC, O'Connor ML: Albuminuria vs urinary total protein for detecting chronic renal disorders. Clin Chem. 1991, 37: 621-624.PubMed
35.
Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988, 2: 530-533. 10.1016/S0140-6736(88)92657-8.CrossRefPubMed
36.
Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, et al: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol. 2004, 15: 219-227. 10.1097/01.ASN.0000101031.52826.BE.CrossRefPubMed
37.
Kolch W, Neususs C, Pelzing M, Mischak H: Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev. 2005, 24: 959-977. 10.1002/mas.20051.CrossRefPubMed
38.
Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, et al: Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007, 6: 4549-4555. 10.1021/pr070529w.CrossRefPubMed
39.
Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P: Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004, 65: 323-332. 10.1111/j.1523-1755.2004.00352.x.CrossRefPubMed
40.
Mischak H, Kolch W, Aivalotis M, Bouyssie D, Court M, Dihazi H, et al: Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl. 2010, 4: 464-478. 10.1002/prca.200900189.CrossRefPubMedPubMedCentral
41.
Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, et al: Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005, 67: 2313-2320. 10.1111/j.1523-1755.2005.00335.x.CrossRefPubMed
42.
Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, et al: Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int. 2004, 65: 2426-2434. 10.1111/j.1523-1755.2004.00659.x.CrossRefPubMed
43.
Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, et al: Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis. 2005, 26: 2797-2808. 10.1002/elps.200400208.CrossRefPubMed
44.
Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, Schiffer E, et al: Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther. 2009, 11: 1-9. 10.1089/dia.2008.0040.CrossRefPubMedPubMedCentral
45.
Andersen S, Brochner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003, 26: 3296-3302. 10.2337/diacare.26.12.3296.CrossRefPubMed
46.
Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, et al: Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis. 2006, 27: 2111-2125. 10.1002/elps.200500827.CrossRefPubMed
47.
Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al: Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006, 7: 230-240. 10.1016/S1470-2045(06)70584-8.CrossRefPubMed
48.
Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, et al: Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Communications in Mass Spectrometry. 2004, 18: 149-156. 10.1002/rcm.1294.CrossRefPubMed
49.
Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, et al: Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. J Proteome Res. 2009, 8: 268-281. 10.1021/pr800401m.CrossRefPubMed
50.
DeLeo JM: DeLeo, J.M. Receiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty. 1993, College Park, MD, USA, 318-325.
51.
Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological). 1995, 57: 125-133.
52.
Coon JJ, Zürbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, et al: CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl. 2008, 2: 964-973. 10.1002/prca.200800024.CrossRefPubMedPubMedCentral
53.
Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM: The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl. 2008, 2: 997-1007. 10.1002/prca.200780166.CrossRefPubMed
54.
Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al: Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010, 2: 46ps42-CrossRefPubMed
Metadata
Title
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
Authors
Sten Andersen
Harald Mischak
Petra Zürbig
Hans-Henrik Parving
Peter Rossing
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2010
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-11-29

Other articles of this Issue 1/2010

BMC Nephrology 1/2010 Go to the issue

Research article

Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival

Research article

Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice

Research article

Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis

Research article

Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study

Research article

Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients

Research article

Pre-dialysis patients' perceived autonomy, self-esteem and labor participation: associations with illness perceptions and treatment perceptions. A cross-sectional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits